{"id":738319,"date":"2025-04-03T15:32:01","date_gmt":"2025-04-03T15:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=738319"},"modified":"2025-04-03T15:32:01","modified_gmt":"2025-04-03T15:32:01","slug":"oligonucleotide-cdmo-market-to-hit-us673-billion-by-2029-with-218-cagr","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/oligonucleotide-cdmo-market-to-hit-us673-billion-by-2029-with-218-cagr_738319.html","title":{"rendered":"Oligonucleotide CDMO Market to Hit US$6.73 Billion by 2029 with 21.8% CAGR"},"content":{"rendered":"
\n
\"Oligonucleotide<\/a><\/div>\n
\n
Key players in the oligonucleotide CDMO market include Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Agilent Technologies, Inc. (US), Kaneka Eurogentec S.A. (Belgium), Ajinomoto Co., Inc. (Japan)<\/div>\n<\/div>\n<\/div>\n
Browse 270 market data Tables and 56 Figures spread through 254 Pages and in-depth TOC on “Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA, (CPG Oligos, gRNA)), Application (Therapeutic, Research, Diagnostic), End User (Pharma, Biotech) – Global Forecast to 2029<\/div>\n

Global Oligonucleotide CDMO Market Poised for Strong Growth<\/strong><\/p>\n

The global Oligonucleotide Contract Development and Manufacturing Organization (CDMO) market<\/a>, valued at US$2.33 billion in 2023<\/strong>, is projected to expand at an impressive CAGR of 21.8%<\/strong>, reaching US$2.51 billion in 2024<\/strong> and US$6.73 billion by 2029<\/strong>. Key drivers of this growth include the increasing outsourcing of drug development and manufacturing to CDMOs and the rising demand for precision and personalized medicine. Additionally, growing investments in oligonucleotide-based therapeutics are further fueling market expansion.<\/p>\n

Request Sample Pages : <\/strong>https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=227700087<\/a><\/strong><\/p>\n

Market Segmentation and Growth DriversDominance of Contract Manufacturing Services<\/strong><\/p>\n

The oligonucleotide CDMO market is categorized into contract development, contract manufacturing, and other services<\/strong>. Among these, the contract manufacturing segment<\/strong> is expected to lead the market, driven by the need for large-scale, cGMP-compliant<\/strong> production of oligonucleotide APIs for both clinical and commercial applications. CDMOs with advanced solid-phase synthesis platforms<\/strong>, high-throughput purification technologies<\/strong>, and automated fill-finish systems<\/strong> are instrumental in meeting the demand for ASOs, siRNAs, and mRNA-based therapeutics<\/strong>.<\/p>\n

Within contract manufacturing, the commercial segment<\/strong> is anticipated to dominate, supported by the rising number of FDA-approved oligonucleotide-based therapeutics<\/strong> and their expanding applications in chronic diseases and oncology<\/strong>. The demand for large-scale manufacturing for late-stage clinical trials and commercial APIs is driving investment in cGMP production capabilities<\/strong>. The growing adoption of lipid nanoparticles for mRNA-based therapies<\/strong> is further propelling the market.<\/p>\n

Therapeutic Applications Leading the Market<\/strong><\/p>\n

The market is segmented by applications<\/strong> into therapeutic, diagnostic, and research applications<\/strong>. In 2023, the therapeutic applications segment<\/strong> held the largest share, driven by increasing oligonucleotide drug approvals<\/strong> targeting genetic disorders, oncology, and rare diseases<\/strong>. Innovations in delivery platforms<\/strong>, such as lipid nanoparticle encapsulation<\/strong>, and stringent regulatory requirements for cGMP manufacturing<\/strong> are solidifying this segment’s dominance.<\/p>\n

Regional Insights: North America & Asia Pacific<\/strong><\/p>\n

The market is geographically divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa<\/strong>. While Asia Pacific registered the highest CAGR in 2023<\/strong>, North America remains the dominant region<\/strong>, driven by its advanced pharmaceutical infrastructure<\/strong>, strong biotech presence<\/strong>, and substantial R&D investments<\/strong> in oligonucleotide therapeutics. The presence of leading CDMOs equipped with automated synthesis<\/strong> and high-throughput purification technologies<\/strong>, along with favorable regulatory frameworks<\/strong>, ensures North America’s continued market leadership.<\/p>\n

Competitive Landscape: Key Players & Strategic Initiatives<\/strong><\/p>\n

The oligonucleotide CDMO market is highly consolidated<\/strong>, with key players implementing various strategies<\/strong>, including product innovations, partnerships, expansions, and acquisitions<\/strong>, to strengthen their market position.<\/p>\n

Leading Companies in the Market:<\/strong><\/p>\n